In the last trading session, 1.12 million Corvus Pharmaceuticals Inc (NASDAQ:CRVS) shares changed hands as the company’s beta touched 0.98. With the company’s per share price at $8.28 changed hands at $0.03 or 0.36% during last session, the market valuation stood at $532.05M. CRVS’s last price was a discount, traded about -20.77% off its 52-week high of $10.00. The share price had its 52-week low at $1.30, which suggests the last value was 84.3% up since then. When we look at Corvus Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.67 million shares, with the 3-month average coming to 745.96K.
Analysts gave the Corvus Pharmaceuticals Inc (CRVS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRVS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Corvus Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.12.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
Instantly CRVS was in green as seen at the end of in last trading. With action -7.28%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 370.45%, with the 5-day performance at -7.28% in the red. However, in the 30-day time frame, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) is -9.01% down. Looking at the short shares, we see there were 2.93 million shares sold at short interest cover period of 3.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 31.0% from its current market value. According to analyst projections, CRVS’s forecast low is 7 with 13 as the target high. To hit the forecast high, the stock’s price needs a -57.0% plunge from its current level, while the stock would need to tank 15.46% for it to hit the projected low.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
Data shows that the Corvus Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 283.33% over the past 6 months, a -66.07% in annual growth rate that is considerably lower than the industry average of 17.60%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.89%. The 2024 estimates are for Corvus Pharmaceuticals Inc earnings to decrease by -65.36%.
CRVS Dividends
Corvus Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.02% of Corvus Pharmaceuticals Inc shares while 44.47% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 46.34%. There are 44.47% institutions holding the Corvus Pharmaceuticals Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.1596% of the shares, roughly 6.94 million CRVS shares worth $12.64 million.
SAMLYN CAPITAL, LLC holds the second largest percentage of outstanding shares, with 12.4861% or 6.12 million shares worth $11.14 million as of 2024-06-30.
